Evidence map›Paper›PMID 42039163›Full record

ArticleFrontiers in immunology2026

Real-world efficacy and safety of transarterial chemoembolization plus sintilimab and bevacizumab biosimilar for intermediate-advanced hepatocellular carcinoma: a propensity score matching study.

Li-Wei Deng, Jun-Feng Liu, Hai-Yan Yu, Bo Peng, Bin Liu, Shi-Feng Feng, Dong-Xu Liu, Yan-Yuan Sun, Yan Chen, Jian-Jian Chen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Li-Wei Deng *Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Jun-Feng Liu *Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Hai-Yan Yu *Department of Oncology, Xuanhan County People's Hospital, Dazhou, Sichuan, China.
Bo Peng *Department of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.
Bin Liu *Department of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China.
Shi-Feng FengDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Dong-Xu LiuDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Yan-Yuan SunDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Yan ChenDepartment of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Jian-Jian ChenDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Chi ZhangDepartment of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Hai-Qing WangDepartment of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Guo-Hui XuDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Le LiuDepartment of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.
Guo WeiDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Yi RenDepartment of Interventional Radiology, Chengdu Second People's Hospital, Chengdu, China.
Lei CaoDepartment of Tumor Vascular Intervention, Chengdu Qingbaijiang District People's Hospital, Chengdu, China.
Yong ZhaoDepartment of General Surgery, Chengdu Public Health Clinical Medical Center, Chengdu, China.
Xue-Gang YangDepartment of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to investigate the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab biosimilar as first-line therapy for intermediate-advanced hepatocellular carcinoma (HCC). Materials and methods: A total of 253 patients with HCC who received either TACE plus sintilimab and bevacizumab biosimilar (combination group, n=74) or TACE alone (monotherapy group, n=179) were included retrospectively. Propensity score matching (PSM) analysis was used to match patients. The objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of two groups were compared. Results: After propensity score matching (1:2), 65 patients in the combination group were matched to 100 patients in the monotherapy group. The ORR (63.1% vs. 40.0%, Conclusion: Compared to TACE monotherapy, TACE plus sintilimab and bevacizumab biosimilar showed significantly better ORR, PFS, and OS for intermediate-advanced HCC.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiosimilar PharmaceuticalsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedBevacizumabBiosimilar Pharmaceuticalssintilimabbevacizumabchemoembolizationcombined modality therapyhepatocellular carcinomaimmunotherapy

Identifiers

PMID42039163
PMCPMC13106286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.